Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
07.29
2021
Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
07.07
2021
Addex Therapeutics to Present at Access to Giving Virtual Conference on July 14, 2021
07.01
2021
Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
06.30
2021
Addex Establishes At-The-Market ADS Equity Sale Program
06.29
2021
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
06.17
2021
Addex Shareholders Approve All Resolutions at Annual General Meeting
06.07
2021
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
05.24
2021
Addex to Participate at the Benchmark Company Healthcare House Call Conference
05.17
2021
Addex’s Dipraglurant Restores Synaptic Plasticity in Models of Dystonia
05.14
2021
Addex Convenes Annual General Meeting 2021
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back